Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 19

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 19
---
 preemptive rights in respect of such issuances and grant of rights, and during this period we may make offers and enter agreements which would or might require shares to be issued or rights to be granted after the expiration of the period and the directors may issue shares or grant rights in pursuance of such offers or agreements as if the authority had not expired. As of February 28, 2025, £52,765.874 of aggregate nominal value of ordinary shares (equivalent to 26,382,937 ordinary shares) previously have been issued or been the subject of grants made under this authority, including in respect of the issuance of the notes in February 2024. To the extent we do not have sufficient

<div align='center'>S-11</div>

#### TABLE OF CONTENTS
**shareholder authority to issue ordinary shares to be represented by ADSs at the time any holder elects to convert its notes, we would be required to settle such conversion (or the relevant portion thereof) in cash as described in the section titled “Description of Notes—Conversion Rights—Conversion Share Limitations.” The indenture requires us to maintain at all relevant times the ability to allot and issue, free of pre-emptive rights and in accordance with all applicable laws, ordinary shares for the purpose of enabling us to satisfy our obligation to issue all of the ordinary shares that may be due upon conversion of the notes (including in connection with a make-whole fundamental change, notice of optional redemption or notice of tax redemption).

Future sales of our ADSs, ordinary shares or equity-linked securities in the public market could lower the market price for our ADSs and adversely impact the trading price of the notes.

In the future, we may sell additional ADSs, ordinary shares or equity-linked securities to raise capital. In addition, substantial numbers of our ADSs and ordinary shares are reserved for issuance upon the exercise of share options and upon conversion of the notes. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price for our ADSs. The issuance and sale of substantial amounts of our ADSs, ordinary shares or equity-linked securities, or the perception that such issuances and sales may occur, could adversely affect the trading price of the notes and the market price of our ADSs and impair our ability to raise capital through the sale of additional equity or equity-linked securities.

Holders of notes are not entitled to any rights with respect to our ordinary shares or ADSs, but are subject